Ophthalmology – Schnyder’s Corneal Dystrophy

What the Disorder Represents

Schnyder corneal dystrophy (SCD) is a rare, bilateral, usually symmetric autosomal dominant stromal corneal dystrophy caused by abnormal deposition of lipids—particularly cholesterol and phospholipids—within the cornea.

Typical changes include:

• Central anterior stromal haze
• Crystalline deposits in some patients
• Progressive corneal arcus
• Increasing midperipheral stromal haze with age

An important modern point is:

Visible corneal crystals are not required for the diagnosis.

For this reason, the preferred name is Schnyder corneal dystrophy, rather than the older term “Schnyder crystalline corneal dystrophy.”

Who Tends to Be Affected

SCD is very uncommon and has been reported worldwide.

Features include:

• Often recognized in childhood or early adulthood
• Slowly progressive over decades
• Usually bilateral
• No strong sex predilection

A historically large pedigree was identified in individuals of:

Swede-Finn ancestry

but the disorder is not confined to this population.

How It Is Inherited

SCD follows an:

Autosomal dominant inheritance pattern

with variable expression.

An affected individual therefore typically has a:

50% chance of transmitting the pathogenic variant to each child

although clinical severity can differ considerably among relatives.

The Main Genetic Defect

SCD is caused by pathogenic variants in:

UBIAD1

located on:

Chromosome 1p36

UBIAD1 encodes a prenyltransferase involved in cellular lipid and cholesterol homeostasis.

Why Lipid Accumulates in the Cornea

Abnormal UBIAD1 function disrupts:

• Intracellular cholesterol handling
• Lipid metabolism
• Sterol trafficking

leading to accumulation of:

• Unesterified cholesterol
• Cholesterol esters
• Phospholipids

within:

• Bowman layer
• Anterior stroma
• Eventually deeper stromal tissue

Relationship to Blood Lipids

SCD is associated with increased frequency of:

• Hypercholesterolemia
• Hypertriglyceridemia

However:

Systemic dyslipidemia is not required for SCD to occur.

A patient can have genetically confirmed SCD with:

• Normal serum cholesterol
• Normal triglycerides

Thus the corneal disorder is primarily due to:

Intrinsic abnormal corneal lipid metabolism.

Other Systemic Associations

Reported associations include:

• Xanthelasma
• Hyperlipidemia
• Premature cardiovascular risk related to dyslipidemia
• Rare historical reports of genu valgum

These associations are not sufficiently specific to diagnose SCD.

How the Cornea Changes With Age

SCD often evolves in a characteristic age-related pattern.

Earlier Years

Patients may develop:

• Central stromal haze
• Fine crystalline deposits

Young to Middle Adulthood

A prominent:

Corneal arcus

may develop.

Later Adulthood

There may be progressive:

• Midperipheral stromal haze
• Generalized corneal clouding
• Loss of transparency

The exact timing varies substantially among families.

The Crystalline Variant

Some patients develop:

Fine, highly refractile polychromatic crystals

within the central anterior stroma.

They may appear:

• Needle-like
• Rectangular
• Plate-like

However, a substantial proportion of affected patients have:

No visible crystals at all.

SCD Without Crystals

The absence of crystals can make the diagnosis more difficult.

Noncrystalline SCD may present primarily with:

• Central haze
• Premature arcus
• Progressive stromal clouding

and can be mistaken for:

• Lipid keratopathy
• Other stromal dystrophies
• Metabolic corneal disease

Family history and genetic testing can be especially helpful in these cases.

Typical Symptoms

Patients may remain asymptomatic for years.

Symptoms can include:

• Glare
• Halos
• Photophobia
• Reduced contrast sensitivity
• Blurred vision

Glare often develops before substantial loss of Snellen visual acuity.

Why Bright Light Can Be Difficult

Deposited lipid and stromal haze scatter incoming light.

This can cause disproportionate visual difficulty under:

Photopic or glare conditions

even when standard visual acuity remains relatively good.

Effect on Visual Acuity

Central acuity is often preserved early.

Progressive visual loss usually results from:

• Increasing central stromal haze
• Broader stromal lipid deposition
• Light scatter

Severe disease can eventually cause:

Clinically significant corneal opacity.

Changes in Corneal Sensation

Corneal sensation may gradually become:

Reduced

over areas of stromal disease.

This is usually a late or progressive finding rather than an early diagnostic hallmark.

What the Slit Lamp Shows

Typical findings include:

• Bilateral central stromal haze
• Crystalline deposits in some patients
• Progressive corneal arcus
• Midperipheral stromal clouding with age

The epithelium is usually:

Relatively normal

because the primary pathology is stromal.

Where the Deposits Are Located

Deposits are typically concentrated in:

• Bowman layer
• Anterior stroma

With progression they can involve:

• Deeper stromal layers

The posterior cornea is relatively spared until advanced disease.

Microscopic Appearance

Histopathology can demonstrate:

• Lipid deposition in Bowman layer and stroma
• Cholesterol crystals
• Disruption of stromal organization

Special lipid stains such as:

Oil Red O

may demonstrate deposited neutral lipid in appropriately processed tissue.

Confocal Microscopy Findings

In vivo confocal microscopy may show:

• Needle-shaped crystals
• Rectangular refractile deposits
• Hyperreflective stromal material

It can support the diagnosis but is:

Not required in a typical case.

How the Diagnosis Is Established

Diagnosis is usually based on:

• Characteristic bilateral corneal appearance
• Family history
• Age-related progression
• Exclusion of systemic crystalline keratopathies

Genetic confirmation is available through:

UBIAD1 testing.

When Genetic Testing Is Most Helpful

Genetic testing is particularly useful when:

• Crystals are absent
• The phenotype is atypical
• Family counseling is needed
• A metabolic or hematologic mimic is being considered

A pathogenic UBIAD1 variant strongly supports the diagnosis.

What Blood Testing Is Worth Doing

Because dyslipidemia occurs relatively frequently, patients should generally have assessment of:

• Fasting or nonfasting lipid profile
• Total cholesterol
• LDL cholesterol
• HDL cholesterol
• Triglycerides

Abnormal results should be managed according to:

General cardiovascular-risk guidelines.

Important Modern Treatment Principle

Lowering serum cholesterol is important when dyslipidemia is present, but:

Lipid-lowering medication does not reliably remove existing corneal deposits or halt the inherited corneal dystrophy.

Statins or other agents should therefore be prescribed for:

• Cardiovascular indications
• Systemic lipid control

rather than as direct corneal therapy.

Disorders That Can Resemble SCD

Important alternatives include:

• Cystinosis
• LCAT deficiency
• Monoclonal gammopathy-associated crystalline keratopathy
• Multiple myeloma-associated corneal deposits
• Infectious crystalline keratopathy
• Gout-related crystalline deposits
• Tangier disease
• Other lipid keratopathies

Distinguishing It From Cystinosis

Schnyder Corneal Dystrophy

• Autosomal dominant
• UBIAD1-related
• Stromal cholesterol/lipid deposition
• Often central haze ± crystals
• Slowly progressive

Cystinosis

• Systemic lysosomal storage disorder
• Cystine crystals
• Dense crystals throughout cornea
• May have renal and systemic disease
• Photophobia often prominent

Distinguishing It From Infectious Crystalline Keratopathy

Infectious crystalline keratopathy typically shows:

• Branching stromal infiltrates
• Infectious context
• Often prior surgery, steroid use, or compromised cornea

SCD is:

• Bilateral
• Slowly progressive
• Noninflammatory
• Hereditary

Distinguishing It From Monoclonal Gammopathy

Crystalline corneal deposits associated with monoclonal gammopathy may signal:

• MGUS
• Multiple myeloma
• Other plasma-cell disorders

These patients may require:

• Serum protein electrophoresis
• Immunofixation
• Hematologic evaluation

when the corneal phenotype is atypical for inherited SCD.

Managing Mild Disease

Patients with good functional vision generally require:

Observation only.

Management may include:

• Updated spectacle correction
• Glare-reducing lenses
• Tinted lenses if helpful

No topical medication has been shown to eliminate the stromal lipid deposits.

Reducing Glare

Patients troubled primarily by glare may benefit from:

• Sunglasses
• Polarized lenses
• Selective tints

These improve symptoms but:

Do not alter disease progression.

When PTK Can Help

Phototherapeutic keratectomy (PTK) can be considered when visually significant deposits are:

• Superficial
• Confined mainly to the anterior cornea

PTK may improve:

• Corneal clarity
• Glare
• Visual acuity

Limitations of PTK

PTK cannot adequately treat:

• Deep stromal disease
• Extensive diffuse haze

It may also cause:

• Hyperopic refractive shift
• Corneal haze
• Recurrence of deposits

because the underlying genetic abnormality remains.

When Corneal Transplantation Is Needed

Advanced visually significant stromal opacity may require:

• Deep anterior lamellar keratoplasty (DALK)
• Penetrating keratoplasty in selected cases

Because the endothelium is generally healthy:

Lamellar transplantation is attractive when technically feasible.

Why DALK Can Be Advantageous

DALK preserves the patient’s own endothelium and therefore avoids:

• Endothelial rejection
• Some long-term endothelial graft complications

It is appropriate when disease is primarily:

Stromal.

When Penetrating Keratoplasty Is Considered

PK may be necessary when:

• Stromal disease is very deep
• Previous surgery has altered anatomy
• DALK is technically unsuitable

Visual prognosis after successful transplantation is generally good.

Recurrence After Surgery

SCD can recur after:

• PTK
• Lamellar grafting
• Penetrating keratoplasty

because recipient keratocytes and the underlying genetic defect remain capable of abnormal lipid handling.

Recurrence is typically:

Slow and may take many years.

Monitoring the Disease Over Time

Stable patients can generally be reviewed periodically, often:

Annually

rather than requiring a fixed 6-month schedule for every patient.

Monitor:

• Visual acuity
• Glare
• Corneal haze
• Crystalline deposition
• Arcus
• Corneal sensation

Closer follow-up is appropriate if:

• Visual function is changing
• Surgery is being considered

Family Evaluation

Because SCD is autosomal dominant, examination of:

• Parents
• Siblings
• Children

may reveal subtle or presymptomatic disease.

Genetic counseling can clarify:

• Transmission risk
• Testing options
• Variable expression

Expected Long-Term Course

The disease generally progresses:

Slowly over decades.

Many patients retain:

• Useful vision
• Good central acuity

for a long period.

A minority eventually develop enough stromal haze to require:

• PTK
• Keratoplasty

Factors Affecting Visual Function

Vision depends more on:

• Extent of stromal haze
• Central opacity
• Light scatter

than on the mere presence of visible crystals.

This explains why:

A patient with few or no crystals may still develop substantial visual impairment.

Potential Long-Term Problems

Possible complications include:

• Progressive stromal haze
• Glare disability
• Reduced contrast sensitivity
• Reduced corneal sensation
• Significant visual impairment
• Recurrence after PTK
• Recurrence within a corneal graft

Ophthalmology Pearls

• Schnyder corneal dystrophy is a rare autosomal dominant stromal dystrophy caused by pathogenic variants in UBIAD1 on chromosome 1p36.
• The fundamental abnormality is corneal cholesterol and phospholipid deposition.
• Crystals are not obligatory, which is why “Schnyder corneal dystrophy” is preferred over the older term “Schnyder crystalline corneal dystrophy.”
• Typical evolution includes central stromal haze ± crystals, premature corneal arcus, and increasing midperipheral stromal haze with age.
• Patients may complain of glare before measurable loss of standard visual acuity.
• Visible deposits are usually concentrated in Bowman layer and the anterior stroma.
• SCD may be associated with hypercholesterolemia and hypertriglyceridemia, but a normal lipid profile does not exclude the diagnosis.
• Obtain a lipid profile because systemic dyslipidemia should be treated for cardiovascular health.
• Lipid-lowering therapy does not reliably clear the corneal deposits and is not a direct treatment for SCD.
• Genetic testing for UBIAD1 is especially helpful in noncrystalline or atypical cases.
• Important mimics include cystinosis, monoclonal gammopathy-related crystalline keratopathy, LCAT deficiency, and infectious crystalline keratopathy.
• Mild disease is usually managed with observation and glare control.
• PTK is useful for selected superficial visually significant deposits.
• Advanced stromal haze may require DALK or penetrating keratoplasty.
• Because the underlying genetic abnormality persists, recurrence can occur after PTK or corneal transplantation, although it is usually slow.
• Visual prognosis is generally favorable, and many affected patients retain useful central vision for decades.